Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.
Clinical Dx Showcase:
OncoHost has developed the PROphet® platform, a plasma-based, proprietary proteomic analysis tool that guides decision-making in the choice of first-line anti-PD-(L)1 treatment regimens for cancer patients, analyzes resistance mechanisms, and suggests potential treatment combinations to overcome this resistance.
Proteomic and AI analysis for late-stage lung cancer
Liquid-based proteomic test to inform first line anti-PD-1/PD-L1 lung treatment decisions
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative